Product Description
Flibanserin is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment, but has not been linked to instances of clinically apparent acute liver injury. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31643404/)
Mechanisms of Action: 5-HT1A Agonist,5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Canada | Egypt | United States
Approved Indications: Generalized anxiety disorder
Known Adverse Events: Dizziness | Insomnia
Company: Sprout
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Erectile Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HSDD | P2 |
Recruiting |
Erectile Dysfunction |
2024-10-31 |